Skip to main content
TipRanks
Go Ultimate75% OFF

Marksans Pharma Limited (MARKSANS) AI Stock Analysis

8 Followers
IN:MARKSANS

Marksans Pharma Limited

(NSE:MARKSANS)

Select Model
Rating:65Neutral
Price Target:INR 329.00â–²(9.98% Upside)
Action:reiterated
Date:11/18/26

Marksans Pharma scores in the moderately favourable range, driven primarily by a strong financial profile: consistent double-digit revenue growth, stable mid-teens net margins, and a conservatively leveraged balance sheet with low debt and steadily compounding equity. The main fundamental caution is inconsistent conversion of profits into free cash flow during FY2024-FY2025, alongside a projected sharp drop in gross margin that needs to be monitored. Technically, the stock retains a healthy long-term uptrend well above its 200-DMA, though it is currently consolidating below its 50-DMA with neutral momentum readings. Valuation at 25x earnings is fair rather than cheap, and the negligible 0.29% dividend yield means returns depend on growth execution. Earnings call and corporate event data were unavailable and therefore excluded, with their weight redistributed across the remaining components.

Positive Factors
Revenue GrowthSustained revenue expansion indicates continued demand for Marksans Pharma’s generic formulations across its markets. A multiyear growth record can support operating scale, broaden customer reach, and create a durable base for future earnings growth if the company maintains execution.
Negative Factors
Gross Margin CompressionThe sharp FY2026 gross-margin decline signals pressure on product economics, pricing, or cost structure. If this deterioration persists, revenue growth may translate into weaker operating leverage and earnings, reducing the durability of the company’s otherwise solid profitability profile.

Marksans Pharma Limited (MARKSANS) vs. iShares MSCI India ETF (INDA)

-20%0%20%40%60%80%100%IN:MARKSANS+58.93%INDA-4.08%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 132.96B
Dividend Yield
0.30%
Average Volume (3M)
123.11K
Price to Earnings (P/E)
24.2
Beta (1Y)
1.00
Revenue Growth
24.20%
EPS Growth
59.18%
Country
India
Employees
1,685
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - General

Marksans Pharma Limited Business Overview & Revenue Model

Company Description

Marksans Pharma Limited, along with its subsidiaries, operates internationally, engaging in the full spectrum of generic pharmaceutical formulation activities, from research and development and manufacturing to marketing, distribution, and sales. The...

Marksans Pharma Limited Financial Statement Overview

Summary

Solid fundamentals overall. Revenue has compounded at roughly 16-17% since FY2021 (₹13.7B to an estimated ₹29.5B in FY2026) with net margins held in the 12-17% band and net income rising steadily to a projected ₹4.18B (Income Statement: 68). The balance sheet is the standout strength, with debt-to-equity consistently below 0.15, equity growing from ₹8.9B to a projected ₹30.2B, and stable ~15% ROE (Balance Sheet: 72). Cash flow is the weak link (Cash Flow: 58) — operating cash conversion has been erratic (OCF/net income as low as 0.28 in FY2022 and 0.43 in FY2025) and free cash flow collapsed to ₹216M in FY2024 and ₹337M in FY2025 before a projected rebound to ₹3.5B in FY2026. Slowing top-line growth (~8% projected) and the sharp projected gross margin compression from ~56% to ~39% temper the score.

Income Statement

68Positive

Balance Sheet

72Positive

Cash Flow

58Neutral
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue33.92B29.51B26.23B21.77B18.52B14.80B
Gross Profit13.90B11.57B14.79B11.03B9.31B7.32B
EBITDA8.04B6.03B5.29B5.09B3.99B3.01B
Net Income5.60B4.18B3.81B3.14B2.66B1.85B
Balance Sheet
Total Assets43.60B38.61B32.40B26.81B21.90B16.40B
Cash, Cash Equivalents and Short-Term Investments11.24B9.90B7.05B7.00B7.19B3.47B
Total Debt4.65B3.43B3.22B2.44B1.23B1.11B
Total Liabilities9.92B8.08B7.50B5.95B4.25B4.17B
Stockholders Equity33.32B30.23B24.67B20.65B17.45B12.02B
Cash Flow
Free Cash Flow03.51B337.45M215.69M1.84B529.27M
Operating Cash Flow04.82B2.07B2.30B2.37B992.57M
Investing Cash Flow0-2.75B-490.09M-1.41B-2.59B-416.86M
Financing Cash Flow0-681.43M-651.46M-687.27M1.98B795.11M

Marksans Pharma Limited Technical Analysis

Technical Analysis SentimentNegative
Last Price299.15

Price Trends

50DMA316.41Negative
100DMA301.12Negative
200DMA248.36Positive

Market Momentum

MACD-2.45Positive
RSI44.49Neutral
STOCH20.44Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:MARKSANS, the sentiment is Negative. The current price of 299.15 is below the 20-day moving average (MA) of 305.65, below the 50-day MA of 316.41, and above the 200-day MA of 248.36, indicating a neutral trend. The MACD of -2.45 indicates Positive momentum. The RSI at 44.49 is Neutral, neither overbought nor oversold. The STOCH value of 20.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:MARKSANS.

Marksans Pharma Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

IN:MARKSANS against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:CIPLAIN:CIPLA73OutperformINR 1.14T39.55―2.05%-0.74%-46.77%
IN:GLAXOIN:GLAXO73OutperformINR 459.88B40.09―2.10%12.12%20.03%
IN:PFIZERIN:PFIZER69NeutralINR 176.12B20.50―1.95%11.75%2.39%
IN:GLANDIN:GLAND66NeutralINR 543.06B43.92―0.61%21.90%56.28%
IN:MARKSANSIN:MARKSANS65NeutralINR 135.56B24.19―0.30%24.20%59.18%
IN:SANOFIIN:SANOFI65NeutralINR 73.70B20.23―3.85%-5.74%2.30%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

0%50%IN:MARKSANSIN:CIPLAIN:GLANDIN:GLAXOIN:PFIZERIN:SANOFIDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:MARKSANS and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:MARKSANSMarksans Pharma Limited299.15110.6258.68%
IN:CIPLACipla Ltd1416.00-73.91-4.96%
IN:GLANDGland Pharma Ltd.3291.051513.4585.14%
IN:GLAXOGlaxoSmithKline Pharmaceuticals Limited2714.65301.1112.48%
IN:PFIZERPFIZER LIMITED3849.70-1045.73-21.36%
IN:SANOFISanofi India Limited3200.15-1050.77-24.72%

Marksans Pharma Limited Corporate Events

Marksans Pharma Files Q2 FY27 Earnings Call Transcript

Nov 13, 2026

Marksans Pharma Limited informed the exchanges on November 13, 2026, that it had submitted the transcript of its investor and analyst meeting on Q2 FY27 unaudited financial results, held on November 5, 2026. The transcript was also made available on...

Marksans Pharma Opens SEBI-Mandated Window for Re-Lodging Physical Share Transfers

Sep 17, 2026

Marksans Pharma Limited has announced the opening of a special window for shareholders to re-lodge transfer requests for physical shares purchased before April 1, 2019 that were previously rejected or not processed due to documentation deficiencies....

Marksans Pharma to Join Elara India Dialogue 2026 Investor Meet

Sep 1, 2026

Marksans Pharma Limited has scheduled participation in the Ashwamedh – Elara India Dialogue 2026, an investor and analyst meeting to be held on 2 September 2026 at the Hyatt in Santacruz East, Mumbai. The company emphasized that no unpublished price-...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 17, 2026